Molecular Surveillance of Antimicrobial Resistance of Mycobacterium leprae from Leprosy Patients in Zhejiang Province, China

References

• World Health Organization = Organisation mondiale de la Santé. Global leprosy (Hansen disease) update, 2020: impact of COVID-19 on global leprosy control –Situation de la lèpre (maladie de Hansen) dans Le Monde, 2020: impact de la COVID-19 sur les activités mondiales de lutte contre la lèpre. Wkly Epidemiol Rec Relevé Épidémiologique Hebd. 2021;96(36):421–444.
   Google Scholar
• World Health Organization. Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser. 1982;675(1–33):1–33.
   Google Scholar
• Ramu G. Single-dose rifampicin, oflaxicin and minocycline (ROM) therapy for single leprosy lesions. Lepr Rev. 1998;69(1):78–82.
   Web of Science ®Google Scholar
• Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy. 2001;21(10 Pt 2):253S–272S. doi:10.1592/phco.21.16.253S.33993
   Web of Science ®Google Scholar
• Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis off Publ Infect Dis Soc Am. 2000;31(Suppl 2):S24–28. doi:10.1086/314056
   PubMed Web of Science ®Google Scholar
• Daniel E, Ebenezer GJ, Job CK. Pathology of iris in leprosy. Br J Ophthalmol. 1997;81(6):490–492. doi:10.1136/bjo.81.6.490
   PubMed Web of Science ®Google Scholar
• Sivaprasad N, Snehalatha S, Lobo D, Aschhoff M, Job CK. Viability of Mycobacterium leprae in lepromatous patients after five years of dapsone monotherapy supplemented with two years of multidrug therapy. Indian J Lepr. 1995;67(4):427–433.
   Google Scholar
• Pearson JM, Rees RJ, Waters MF. Sulphone resistance in leprosy. A review of one hundred proven clinical cases. Lancet Lond Engl. 1975;2(7924):69–72. doi:10.1016/S0140-6736(75)90508-5
   Web of Science ®Google Scholar
• Cambau E, Carthagena L, Chauffour A, Ji B, Jarlier V. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy. Clin Infect Dis. 2006;42(2):238–241. doi:10.1086/498506
   Web of Science ®Google Scholar
• Honore N, Cole ST. Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother. 1993;37(3):414–418. doi:10.1128/AAC.37.3.414
   PubMed Web of Science ®Google Scholar
• Emmanuelle C, Bonnafous P, Evelyne P, Sougakoff W, Baohong J, Vincent J. Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin Infect Dis. 2002;34(1):39–45. doi:10.1086/324623
   Web of Science ®Google Scholar
• Kai M, Fafutis-Morris M, Miyamoto Y, et al. Mutations in the drug resistance-determining region of Mycobacterium lepromatosis isolated from leprosy patients in Mexico. J Dermatol. 2016;43(11):1345–1349. doi:10.1111/1346-8138.13483
   Web of Science ®Google Scholar
• Comas I, Borrell S, Roetzer A, et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet. 2012;44(1):106–110. doi:10.1038/ng.1038
   Web of Science ®Google Scholar
• Benjak A, Avanzi C, Singh P, et al. Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium leprae. Nat Commun. 2018;9(1):352. doi:10.1038/s41467-017-02576-z
   PubMed Web of Science ®Google Scholar
• Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. New insights into fluoroquinolone resistance in mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One. 2012;7(6):e39754. doi:10.1371/journal.pone.0039754
   PubMed Web of Science ®Google Scholar
• Wu L, Shen Y, Yao Q, et al. Temporal-spatial distribution characteristics of leprosy: a new challenge for leprosy prevention and control in Zhejiang, China. PLoS Negl Trop Dis. 2021;15(1):e0008956. doi:10.1371/journal.pntd.0008956
   Web of Science ®Google Scholar
• Gelber RH, Grosset J. The chemotherapy of leprosy: an interpretive history. Lepr Rev. 2012;83(3):221–240. doi:10.47276/lr.83.3.221
   Web of Science ®Google Scholar
• Faust L, Klowak M, MacRae C, Kopalakrishnan S, Showler AJ, Boggild AK. Ofloxacin-containing multidrug therapy in ambulatory leprosy patients: a case series. J Cutan Med Surg. 2021;25(1):45–52. doi:10.1177/1203475420952437
   Web of Science ®Google Scholar
• Balagon MF, Cellona RV, Abalos RM, Gelber RH, Saunderson PR. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy. Lepr Rev. 2010;81(1):27–33. doi:10.47276/lr.81.1.27
   Web of Science ®Google Scholar
• Lee SB, Kim SK, Kang TJ, et al. The prevalence of folP1 mutations associated with clinical resistance to dapsone, in Mycobacterium leprae isolates from South Korea. Ann Trop Med Parasitol. 2001;95(4):429–432. doi:10.1080/00034983.2001.11813656
   Web of Science ®Google Scholar
• Chokkakula S, Chen Z, Wang L, et al. Molecular surveillance of antimicrobial resistance and transmission pattern of Mycobacterium leprae in Chinese leprosy patients. Emerg Microbes Infect. 2019;8(1):1479–1489. doi:10.1080/22221751.2019.1677177
   PubMed Web of Science ®Google Scholar
• Chauffour A, Morel F, Reibel F, et al. A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance. Clin Microbiol Infect. 2021;27(11):1601–1612. doi:10.1016/j.cmi.2021.07.007
   Web of Science ®Google Scholar
• Jian-Ping S, Gupte MD, Cheng J, Manickam P, Meiwen Y, Zhong LW. Trends of case detection and other indicators of leprosy in China during 1985–2002. Chin Med Sci J Chung-Kuo Hsueh Ko Hsueh Tsa Chih. 2005;20(2):77–82.
   Google Scholar
• Jing Z, Zhang R, Zhou D, Chen J. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy. Lepr Rev. 2009;80(2):170–176.
   PubMed Web of Science ®Google Scholar
• Avanzi C, Maia RC, Benjak A, et al. Emergence of mycobacterium leprae rifampin resistance evaluated by whole-genome sequencing after 48 years of irregular treatment. Antimicrob Agents Chemother. 2020;64(7):e00330–20. doi:10.1128/AAC.00330-20
   Web of Science ®Google Scholar
• Lavania M, Singh I, Turankar RP, et al. Enriched whole genome sequencing identified compensatory mutations in the RNA polymerase gene of rifampicin-resistant Mycobacterium leprae strains. Infect Drug Resist. 2018;11:169–175. doi:10.2147/IDR.S152082
   PubMed Web of Science ®Google Scholar
• Pantel A, Petrella S, Veziris N, et al. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother. 2012;56(4):1990–1996. doi:10.1128/AAC.06272-11
   Web of Science ®Google Scholar
• Zharkov DO. Base excision DNA repair. Cell Mol Life Sci CMLS. 2008;65(10):1544–1565. doi:10.1007/s00018-008-7543-2
   PubMed Web of Science ®Google Scholar
• Moolla N, Goosens VJ, Kana BD, Gordhan BG. The contribution of Nth and Nei DNA glycosylases to mutagenesis in Mycobacterium smegmatis. DNA Repair. 2014;13:32–41. doi:10.1016/j.dnarep.2013.11.003
   Web of Science ®Google Scholar
• Ford CB, Shah RR, Maeda MK, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. 2013;45(7):784–790. doi:10.1038/ng.2656
   PubMed Web of Science ®Google Scholar
• Shen J, Yan L, Sun P. Clinical features of relapse after multidrug therapy for leprosy in China. Lepr Rev. 2015;86(2):165–169. doi:10.47276/lr.86.2.165
   PubMed Web of Science ®Google Scholar
• Xiao YH, Wang J, Li Y; MOH National Antimicrobial Resistance Investigation Net. Bacterial resistance surveillance in China: a report from Mohnarin 2004–2005. Eur J Clin Microbiol Infect Dis off Publ Eur Soc Clin Microbiol. 2008;27(8):697–708. doi:10.1007/s10096-008-0494-6
   PubMed Web of Science ®Google Scholar
• Fontana C, Favaro M, Minelli S, et al. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob Agents Chemother. 2002;46(12):3765–3769. doi:10.1128/AAC.46.12.3765-3769.2002
   PubMed Web of Science ®Google Scholar
• De Francesco V, Zullo A, Giorgio F, et al. Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy. J Med Microbiol. 2014;63(Pt 3):453–457. doi:10.1099/jmm.0.067942-0
   PubMed Web of Science ®Google Scholar
• Gunawan H, Sasmojo M, Putri HE, Avriyanti E, Hindritiani R, Suwarsa O. Clinical pilot study: clarithromycin efficacy in multibacillary leprosy therapy. Int J Mycobacteriology. 2018;7(2):152–155. doi:10.4103/ijmy.ijmy_58_18
   PubMed Web of Science ®Google Scholar
• Lockwood DN, Reid AJ. The diagnosis of leprosy is delayed in the United Kingdom. QJM Mon J Assoc Physicians. 2001;94(4):207–212. doi:10.1093/qjmed/94.4.207
   Web of Science ®Google Scholar